摘要
目的探讨普瑞巴林治疗多发性硬化疼痛的临床疗效及安全性。方法将120例多发性硬化伴疼痛患者按随机数字表法分为对照组及观察组,各60例。对照组患者常规给予激素冲击治疗,观察组患者在对照组基础上加用普瑞巴林胶囊治疗。两组均以4周为1个疗程。观察两组患者的临床症状及体征;采用疼痛视觉模拟评分法(VAS)评价疼痛症状强度,并记录患者疼痛相关的睡眠干扰及抑郁焦虑程度,以及不良反应的发生情况。结果治疗后,两组Kurtzke扩充致残量表(EDSS)评分较治疗前均有显著下降(P<0.05),但组间比较无明显差异(P>0.05);两组患者治疗后同时点有效率比较,差异无统计学意义(P>0.05);两组患者疼痛症状均明显改善,VAS评分均较治疗前明显下降(P<0.05),且观察组治疗2周后VAS评分明显低于同期对照组(P<0.05);两组疼痛相关的睡眠干扰评分、汉密尔顿抑郁量表(HAMD)与汉密尔顿焦虑量表(HAMA)评分均较治疗前显著下降(P<0.05),且治疗2周后观察组各项评分均低于同期对照组(P<0.05);治疗期间,两组各项不良反应发生率比较,无显著性差异(P>0.05)。结论在常规疗法基础上加用普瑞巴林治疗多发性硬化能更有效减轻疼痛症状,且可显著改善患者疼痛相关的睡眠及焦虑抑郁情绪障碍,不良反应较少,药物耐受性良好,值得推广。
Objective To investigate clinical efficacy and safety of the pregabalin in treasting multiple sclerosis pain. Methods 120 cas- es of multiple sclerosis with pain symptoms were randomly divided into the control group and the observation group, 60 cases in each group. The control group was given conventional therapy;the observation group was given Pregabalin Capsules on the basis of the control group. 4 weeks was 1 course of treatment for both groups. The clinical symptoms and signs in the two groups were observed, and the clinical efficacy was evaluated. VAS was used to evaluate the intensity of pain symptoms,and to record the sleep disturbance and the degree of depression and anxiety. The adverse reactions of the two groups were recorded. Results After treatment, the EDSS score of the two groups were significantly decreased（P 〈 0.05）,but there was no significant difference between the two groups（P 〉 0. 05）;the total effective rate of the two groups was not statistically significant（P 〉 0. 05）. The pain symptom was significantly improved in the two groups,the VAS scores were significantly lower than before treatment（P 〈 0. 05）,and the observation group was lower than that in the control group at 2 weeks after treatment（P 〈 0.05）. Compare with before treatment,two groups of pain related sleep disturbance score,HAMD and HAMA score were significantly decreased（P 〈 0.05）,and the observation group after 2 weeks of treatment were significanitly lower than the control group（ P 〈 0. 05）. There was no significant difference in the incidence of adverse reactions between the two groups（ P 〉 0. 05）. Conclusion Pregabalin for treating multiple sclerosis on the basis of conventional therapy application,can be more effective for redueing pain symptoms,and can significantly improve pain in patients with the sleep,anxiety and depression mood disorders,with fewer adverse reactions and drug resistance,which is worthy of promotion.
出处
《中国药业》
CAS
2016年第12期46-48,共3页
China Pharmaceuticals
关键词
普瑞巴林
多发性硬化
疼痛
临床疗效
pregabalin
multiple sclerosis
pain
clinical efficacy
